An international expert consensus statement has been released on the management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants. The statement appears to be part of a broader effort to address the diagnosis and management of these rare neuroendocrine cancers, with various reports and updates also focusing on specific aspects such as genetics, screening, and treatment of related conditions. The exact details and recommendations of the consensus statement are not specified, but it suggests a collaborative approach to improving care for affected patients.